In the News
Monday, November 22, 2010

Ardea Announces Data on MEK Inhibitor BAY 86-9766 RDEA119 to be Presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Published Results Show Denosumab Superior to Zometa® in Delaying or Preventing Bone Complications in Patients With Bone Metastases From Advanced... 11/22/2010 Pharma Business Week

Semaflore Pharmaceuticals Receives FDA Orphan Drug Designation for SF1126 in the Treatment of Chronic Lymphocytic Leukemia 11/22/2010 Pharma Business Week

California Pizza Kitchen to open today at Tucson Mall (benefits Diamond Children's Center) 11/22/2010 TucsonCitizen.com

Pneumococcal disease: A red flag in heart disease management (Dr. Joseph Alpert) 11/21/2010 Cardiology Today

Man dead in apt. attack was Richard Fisher, 22 11/21/2010 AZ Daily Star

Disputed BP shooting now in exclusive hands of feds 11/21/2010 Nogales International

CSI Phoenix: New biotech company aims to help police solve crimes 11/20/2010 Business Review - Online

SRP gives UA $500,000 for scholarship, programs (Dr. Mark Haussler) 11/20/2010 Phoenix Business Journal

How to stop inflammation (the University of Arizona's Center for Integrative Medicine) 11/20/2010 Chatelaine - English Edition - Online

Local group helps breast cancer patients 'Reach to Recovery' 11/20/2010 The Daily Courier

Give The Love Of Reading (COM-Phoenix Public Health) 11/20/2010 Healthnewsdigest.com

Environmental Links to Prostate 11/20/2010 Healthnewsdigest.com
Ardea Announces Data on MEK Inhibitor BAY 86-9766 RDEA119 to be Presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
11/22/2010
Clinical Trials Week

Ardea Biosciences, Inc. (Nasdaq: RDEA) announced that data from preclinical and clinical trials of BAY 86-9766 (formerly known as RDEA119) will be presented at the 22nd European Organisation for Research and Treatment of Cancer (EORTC) - National Cancer Institute (NCI) - American Association for Cancer Research (AACR) symposium on "Molecular Targets and Cancer Therapeutics" in Berlin, Germany. BAY 86-9766 is a mitogen-activated ERK kinase (MEK) inhibitor licensed to and being developed by Bayer HealthCare AG (see also ).

The results of a multi-center, Phase 1, monotherapy, dose-escalation study of BAY 86-9766 in advanced cancer patients will be presented by Colin Weekes, MD, PhD, Assistant Professor, Division of Medical Oncology at the University of Colorado School of Medicine. The principal investigators for this study included Dr. Weekes, Daniel D. Von Hoff, MD, Professor of Medicine at the University of Arizona School of Medicine and Executive Vice President of the Translational Genomics Research Institute (TGen), and Alex Adjei, MD, PhD, Professor and Chair, Department of Medicine at the Roswell Park Cancer Institute. In addition, data from preclinical studies of BAY 86-9766, demonstrating its potential for administration in combination with other anti-cancer agents will be presented by Bayer.

"Based on the good tolerability and impressive number of patients who achieved stable disease in this Phase 1 monotherapy trial in refractory patients with advanced solid tumors, we believe BAY 86-9766 has the potential to be a clinically important drug in the treatment of patients across multiple tumor types," said Dr. Adjei. "These monotherapy results support our ongoing Phase 1/2 study of BAY 86-9766 in combination with sorafenib at the maximum tolerated dose defined in this trial and the continued research by Bayer Healthcare on this important new targeted therapy."

Published Results Show Denosumab Superior to Zometa® in Delaying or Preventing Bone Complications in Patients With Bone Metastases From Advanced Breast Cancer
11/22/2010
Pharma Business Week

Published Results Show Denosumab Superior to Zometa® in Delaying or Preventing Bone Complications in Patients With Bone Metastases From Advanced Breast Cancer
Amgen (Nasdaq: AMGN) announced the publication of results from a pivotal Phase 3 study of 2,046 patients which compared denosumab with Zometa® (zoledronic acid) in delaying or preventing skeletal-related events (SREs) in breast cancer patients with bone metastases. An SRE consists of any of the following: a pathologic fracture, the need for radiation or surgery to ameliorate bone pathology secondary to tumor growth, or spinal cord compression. The study, published in the Journal of Clinical Oncology, found that denosumab was superior to Zometa in delaying or preventing SREs in breast cancer patients with bone metastases (see also ).

"Patients with bone metastases from cancer are at increased risk of experiencing debilitating pathologic fractures and other skeletal-related events. The results of this study show that denosumab is better than the current standard of care (Zometa) in delaying or preventing these skeletal complications for our patients with advanced breast cancer," said Alison Stopeck, M.D., associate professor of Medicine, Arizona Cancer Center, University of Arizona Health Sciences Center. "In addition to improving skeletal outcomes, denosumab has no requirement for
renal monitoring and is administered as a simple subcutaneous injection."

Copyright © 2010 Pharma Business Week via NewsRx.com

Semaphore Pharmaceuticals Receives FDA Orphan Drug Designation for SF1126 in the Treatment of Chronic Lymphocytic Leukemia

11/22/2010

Pharma Business Week

Semaphore Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company’s SF1126 product candidate for the treatment of B-cell chronic lymphocytic leukemia (CLL). In April 2010, the Company initiated an expansion of its ongoing Phase I clinical study into this disease setting. SF1126 is a novel peptidic prodrug that converts to LY294002, one of the most widely studied small molecule inhibitors of both phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) (see also ).

"SF1126 is the first PI3K inhibitor to receive orphan drug designation from the FDA for the treatment of CLL, which is an important milestone for Semaphore Pharmaceuticals," said Joseph Garlich, Ph.D., Semaphore’s Chief Scientific Officer. "We are committed to developing SF1126 as a potential treatment for this disease and look forward to presenting interim clinical data at ASH."

SF1126 will be the subject of a poster presentation at the 52nd American Society of Hematology (ASH) Annual Meeting and Exposition being held December 4-7, 2010 in Orlando, FL. A summary of the presentation is below, and the full abstract can be accessed on the ASH website at www.hematology.org. Phase I Study of Novel Prodrug Dual PI3K/mTOR Inhibitor SF1126 In B-Cell Malignancies Saturday, December 4, 2010, 5:30 p.m. to 7:30 p.m. Eastern Time (ET)

Abstract number: 1783
Poster Session: Lymphoma - Chemotherapy, excluding Pre-Clinical Models: Poster I
Location: Hall A3/A4, Poster Board I-763
Senior author: Daruka Mahadevan, MD, Ph.D., Arizona Cancer Center, University of Arizona, Tucson, AZ
Copyright © 2010 Pharma Business Week via NewsRx.com